School of Pharmacy
  • Print
   
   

Image of Zheying Zhu

Zheying Zhu

Associate Professor in International Pharmacy & Traditional Medicines, Faculty of Science

Contact

Biography

I attained BSc Pharmacy (1982 - 1986) and MSc Biopharmaceutics & Pharmacokinetics (1986 - 1989) from China Pharmaceutical University, following which I was appointed as Lecturer in Pharmaceutics at the same university (1989 - 1991). I attained my PhD in 1992 under the supervision of Professor Mike Richards in the School of Pharmacy, The Robert Gordon University (Scotland, UK). After completing my PhD studies in 1995, I spent two years working as a post-doc fellow in the Department of Pharmacy, The Chinese University of Hong Kong. In 1997 I returned to the UK to continue my research of topical drug delivery at the Department of Pharmacy, King's College London, and developed label-free quantitative Proteomics with its application for toxicology research in the laboratory of Professor Allan Boobis and Dr Rob Edwards at the Centre of Therapeutics and Toxicology, Imperial College London. In 2010 I was appointed as Senior Lecturer of Pharmacology in the Department of Life Sciences, University of Bedfordshire and developed and led the MSc Pharmacology course. In 2016 I joined the School of Pharmacy at Nottingham as Associate Professor and the course Director of the BSc International Pharmacy, a part of the first UK-China Joint Clinical Pharmacy program.

In addition to my academic career, I am a registered pharmacist with the General Pharmaceutical Council of Great Britain, and have practicing experience in community pharmacy with Boots the Chemist and local pharmacies.

Teaching Summary

New course development & management:

BSc International Pharmacy; MSc Pharmacology course

Module teaching delivery and management:

Undergraduate level: some lectures/workshops of B31BIP, B31ESP, B31DYS,B31BFI, B32GLD, B32AID, B32CVI, B32RAE, B32PAI and B32SPE; System Pharmacology

Postgraduate level: Molecular Pharmacology; Drug Discovery & Development; Clinical Pharmacology & Therapeutics; Biomaterials & Tissue Engineering

Research Summary

My current research interest lies in molecular pharmacology combined with drug delivery of novel natural product-derived drugs. This spans across over interdisciplinary technologies, including cell… read more

Recent Publications

  • J CHEN, T WANG, S XU, A LIN, H TAO, W XIE, Z ZHU and J XU, 2017. Design, synthesis and biological evaluation of novel nitric oxide-donating protoberberine derivatives as anti-tumor agents European Journal of Medicinal Chemistry. 132, 173-183
  • J CHEN, R WANG, T WANG, Q DING, A KHALIL, S XU, A LIN, H YAO, W XIE, Z ZHU and J XU, 2017. Antioxidant properties of novel dimers derived from natural β-elemene through inhibiting H2O2-induced apoptosis ACS Medicinal Chemistry Letters. 8(4), 443-448
  • J CHEN, T WANG, S XU, P ZHANG, A LIN, L WU, H YAO, W XIE, Z ZHU and J XU, 2017. Discovery of novel antitumor nitric oxide-donating β-elemene hybrids through inhibiting the PI3K/Akt pathway European Journal of Medicinal Chemistry. 135, 414-423
  • XU S, YAO H, PEI L, HU M, LI DB, QIU Y, WANG, WU L, YAO H, ZHU Z, XU J, 2017. Design, synthesis, and biological evaluation of NAD(P)H: Quinone oxidoreductase (NQO1)-targeted oridonin prodrugs possessing indolequinone moiety for hypoxia-selective activation European Journal of Medicinal Chemistry. 132, 310-321

Current Research

My current research interest lies in molecular pharmacology combined with drug delivery of novel natural product-derived drugs. This spans across over interdisciplinary technologies, including cell biology, systems biology (proteomics, genomics, metabolomics), molecular pharmaceutics, nanotechnology, to evaluate the therapeutic and toxic effects and explore molecular mechanisms of drugs or drug delivery systems.

The research projects currently available in my group include:

1) Development of novel nanosystems for enhanced or targeted delivery of anti-cancer drugs locally and systemically, visualise molecular dynamics and evaluation of drug delivery systems at cellular and molecular levels in vitro and in vivo.

2) Pharmacological studies and target validation pathway of new drug candidates using Drosophila models and 3D iPSC-derived CNS in vitro models in the treatment of Alzheimer's disease

3) Evaluation of anti-bacterial efficacy of natural pure compounds and their novel derivatives on antibiotic resistance, explore molecular mechanism of antibiotic resistance at cellular and molecular levels in vitro and in vivo.

4) Cellular pharmacokintics using advanced analytical and imaging techniques

5) Drug formulation and delivery

We are always looking for new research members to join the group to experience the excitement of research and make new discoveries. Places for research students (PhD or MRes) are available on all the above projects. Please get in touch to discuss if you are interested in the research areas. For international students, there are scholarship schemes to receive support, please get in touch for up to date information.

  • J CHEN, T WANG, S XU, A LIN, H TAO, W XIE, Z ZHU and J XU, 2017. Design, synthesis and biological evaluation of novel nitric oxide-donating protoberberine derivatives as anti-tumor agents European Journal of Medicinal Chemistry. 132, 173-183
  • J CHEN, R WANG, T WANG, Q DING, A KHALIL, S XU, A LIN, H YAO, W XIE, Z ZHU and J XU, 2017. Antioxidant properties of novel dimers derived from natural β-elemene through inhibiting H2O2-induced apoptosis ACS Medicinal Chemistry Letters. 8(4), 443-448
  • J CHEN, T WANG, S XU, P ZHANG, A LIN, L WU, H YAO, W XIE, Z ZHU and J XU, 2017. Discovery of novel antitumor nitric oxide-donating β-elemene hybrids through inhibiting the PI3K/Akt pathway European Journal of Medicinal Chemistry. 135, 414-423
  • XU S, YAO H, PEI L, HU M, LI DB, QIU Y, WANG, WU L, YAO H, ZHU Z, XU J, 2017. Design, synthesis, and biological evaluation of NAD(P)H: Quinone oxidoreductase (NQO1)-targeted oridonin prodrugs possessing indolequinone moiety for hypoxia-selective activation European Journal of Medicinal Chemistry. 132, 310-321
  • S XU, H YAO, M HU, D LI, Z ZHU, W XIE, H YAO, L WU, ZS CHEN AND JXU, 2017. 6,7-Seco-ent-Kauranoids Derived from Oridonin as Potential Anticancer Agents Journal of Natural Products. 80(9), 2391-2398
  • WENLONG LI, HONGHAO SUN, SHENGTAO XU, ZHEYING ZHU & JINYI XU, 2017. Tubulin inhibitors targeting the colchicine binding site: a perspective of privileged structures Future Medicinal Chemistry. 9(15), 1765-1794
  • JIA WANG, CHAOLEI WANG, ZHENG WU, XINNAN LI, SHENGTAO XU, JIE LIU, QINYING LAN, ZHEYING ZHU, JINYI XU, 2017. Design, synthesis, biological evaluation and docking study of 4-isochromanone hybrids bearing N-benzyl pyridinium moiety as dual binding site acetylcholinesterase inhibitors (partⅡ) Chemical Biology & Drug Design.
  • YAO H, LIU J, XU S, ZHU Z, XU J, 2016. The structural modification of natural products for novel drug discovery EXPERT OPINION ON DRUG DISCOVERY. http://dx.doi.org/10.1080/17460441.2016.1272757
  • VAN EIJL S, ZHU Z, CUPITT J, GIERULA M, GOTZ C, FRITSCHE E, EDWARDS R J, 2012. Elucidation of Xenobiotic Metabolism Pathways in Human Skin and Human Skin Models by Proteomic Profiling PLoS One. 7(7): e41721
  • ZHU Z, EDWARDS RJ, 2011. Application of proteomics to study mechanisms of toxicity and dose-response relationships of chemical exposure. In: Handbook of Systems Toxicology John Wiley & Sons, Ltd. p255-p264
  • ZHU Z, EDWARDS R J, BOOBIS A R, 2009. Increased Expression of Histone Proteins during Estrogen-Mediated Cell Proliferation Environmental Health Perspectives. 117, 928-934
  • ZHU Z, BOOBIS A R, EDWARDS R J, 2008. Identification of estrogen-responsive proteins in MCF-7 human breast cancer cells using label-free quantitative proteomics Proteomics. 8, 1987-2005
  • ZHU Z, EDWARDS R J, BOOBIS A R, 2008. Proteomic analysis of human breast cell lines using SELDI-TOF MS shows that mixtures of estrogenic compounds exhibit simple similar action (concentration additivity) Toxicology Letters. 181, 93-103
  • ZHU Z, HOCHKISS SA, BOOBIS AR, EDWARDS RJ, 2002. Expression of P450 enzymes in rat whole skin and cultured epidermal keratinocytes Biochemical and Biophysical Research Communications. 297(1), 65-70
  • LI RC, ZHU ZY, 2002. The integration of four major determinants of antibiotic action: bacterial activity, postantibiotic effect, susceptibility, and pharmacokinetics Journal of Chemotherapy. 14(6), 579-583
  • ZHU ZY, LI RC, 1998. Impact of pharmacokinetics on the postantibiotic effect exhibited by Pseudomonas aeruginosa following tobramycin exposure: application of an in-vitro model Journal of Antimicrobial Chemotherapy. 42(1), 61-65
  • LI RC, ZHU ZY, LEE SW, RAYMOND K, LING JM, CHENG AF, 1997. Antibiotic exposure and its relationship to postantibiotic effect and bacterial activity: constant versus exponentially decreasing tobramycin concentrations against Pseudomonas aeruginosa Antimicrobial Agents and Chemotherapy. 8
  • LI RC, ZHU ZY, 1997. In vitro models for prediction of antimicrobial activity: a pharmacokinetic and pharmacodynamic perspective Journal of Chemotherapy. 9(S1), 55-63
  • RICHARDS RM, TAYLOR RB, ZHU ZY, 1996. Mechanism for synergism between sulphonamides and trimethoprim clarified Journal of Pharmacy and Pharmacology. 48(9), 981-984
  • ZHU ZY, MAO FF, ZHU JB, 1990. Studies on the bioavailability of nitrendipine tablet Yao Xue Xue Bao. 25(9), 709-716
  • ZHU ZY, MAO FF, ZHU JB, 1990. Bioavailability and pharmacokinetics of nitrendipine new formulation capsule in healthy volunteers Journal of China Pharmaceutical University. 21, 77-80
  • ZHU ZY, MAO FF, ZHU JB, 1990. Bioavailability and pharmacokinetics of controlled release nitrendipine tablet in healthy volunteers Chinese Journal of Pharmaceuticals. 21, 499-502

School of Pharmacy

University of Nottingham
University Park
Nottingham, NG7 2RD

For all enquiries please visit:
www.nottingham.ac.uk/enquiry